
|Articles|June 28, 2016
Norgine Divests MENA Operations and Products to Switzerland's Acino
June 28, 2016
Advertisement
Norgine (Amsterdam, The Netherlands) has completed the divestment of its MENA (Middle East and Africa) operations and rights for a number of its products in MENA to Acino (Aesch, Switzerland).
Kalle Känd, CEO of Acino said: “The products [MOVICOL, MOVIPREP, KLEAN-PREP and NORMACOL] are complementary to our existing portfolio in these markets and will considerably strengthen our offer in one of our core therapeutic areas – gastroenterology.”
The transaction includes the transfer of Norgine’s employees and entities in Egypt and employees in Tunisia. Norgine will continue to manufacture its own products for Acino.
Financial terms were not disclosed.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors
2
Executive Order Cuts Recommended Childhood Vaccines Down to 11: Report
3
BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies
4
The Science of Targeting Multiple Immune Components in ITP: Q&A with Dr. Srikanth Nagalla
5




